FRBRX Mutual Fund

FRBRX Mutual Fund (Franklin Biotechnology Discovery Fund Class R6) is managed by Franklin Templeton Investments (US) with $6.2M in net assets. FRBRX expense ratio is 0.67%, holding 98 positions across sectors including Health Care, Financials. Inception date: 2013-05-01.

FRBRX performance shows a YTD return of 17.98%. The 1-year return is 72.02% and the 5-year return is 12.22%. FRBRX dividend yield stands at 1.89%, paid annually.

FRBRX top holdings include Gilead Sciences (6.2%), Amgen Inc. (4.8%), Nvaesrtex Pharmaceuticals Inc (4.7%), Jazz Pharmaceuticals Plc. (4.6%), Regeneron Pharmaceuticals, Inc. (4.4%). Go to all FRBRX holdings, FRBRX sectors, or FRBRX dividends.

FRBRX can be compared against other funds. Use FRBRX overlap to find shared positions, or FRBRX vs another fund for a side-by-side view. FRBRX alternatives are available via the screener, along with tax-loss harvesting opportunities.